Osteosarcoma Clinical Trials

Find Osteosarcoma Clinical Trials Near You

Biologically-Adapted, Dose-Escalated Accelerated Radiotherapy for Ewing Sarcoma (BEAR)

Status: Recruiting

Location: See location...

Intervention Type: Procedure, Other, Radiation, Drug

Study Type: Interventional

Study Phase: Not Applicable

SUMMARY

This clinical trial evaluates the effect of radiotherapy doses based on tumor size and tumor-specific characteristics (biologically-adapted) in treating patients with Ewing sarcoma. Radiotherapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Conventional radiotherapy uses minimal imaging support to determine the positioning of radiotherapy. Hypofractionated radiotherapy delivers higher doses of radiotherapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Dose-escalated radiotherapy uses doses that are higher than those used in conventional radiotherapy. Larger tumor sizes and other tumor-specific characteristics have been shown to be related to poorer outcomes. In addition, after dose-escalated radiotherapy, patients with larger tumors have demonstrated improved control of the disease at the primary tumor site. Giving biologically-adapted, dose-escalated radiotherapy may reduce the return of the cancer at the primary tumor site in patients with Ewing sarcoma with large tumors and other unfavorable characteristics. This clinical trial also evaluates the role of biomarkers in patients with Ewing sarcoma. Studying samples of blood and tumor tissue from patients with Ewing sarcoma in the laboratory may help doctors learn more about predicting the amount of disease and the likelihood of the cancer coming back.

Eligibility

Participation Requirements

Sex: All

Minimum Age: 2

Healthy Volunteers: f

View:

⁃ PRE-REGISTRATION: INCLUSION CRITERIA

• Histological confirmation of Ewing sarcoma, including both skeletal and extra-skeletal primary tumors. Patients with Ewing-like sarcoma may be eligible if patients are planned to be treated per Ewing treatment paradigms, as defined in this clinical trial REGISTRATION: INCLUSION CRITERIA

• Patients of age ≥ 2 years are eligible for the study

• Lansky or Karnofsky performance status ≥ 70

• Ability to provide written informed consent and complete questionnaire(s) by themselves or with assistance

• Willing to provide blood samples for correlative research purposes

• COHORT A ONLY: Willing to provide biopsy sample to run Mayo Complete Solid Tumor Panel

Locations

United States

Minnesota

Mayo Clinic in Rochester

RECRUITING

Rochester

Contact Information

Primary

Clinical Trials Referral Office

mayocliniccancerstudies@mayo.edu

855-776-0015

Time Frame

Start Date: 2025-11-24

Estimated Completion Date: 2029-12-31

Participants

Target number of participants: 141

Treatments

Experimental: Cohort A Group 1 (dose-escalated radiotherapy)

Patients may receive SOC chemotherapy every 2 weeks for at least 3 cycles prior to radiotherapy. Patients then undergo hypofractionated or conventional dose-escalated radiotherapy daily, excluding weekends and holidays, for 25-36 treatment fractions in the absence of disease progression or unacceptable toxicity. Patients may also receive consolidation chemotherapy after completion of radiotherapy and/or surgical resection. Patients also undergo blood sample collection throughout the study. Additionally, patients may also undergo CT, PET/CT, and MRI with or without CT throughout the study at treating clinician's discretion.

Experimental: Cohort A Group 2 (standard dose radiotherapy)

Patients may receive SOC chemotherapy every 2 weeks for at least 3 cycles prior to radiotherapy. Patients then undergo hypofractionated or conventional standard dose radiotherapy daily, excluding weekends and holidays, for 25-31 treatment fractions in the absence of disease progression or unacceptable toxicity. Patients may also receive consolidation chemotherapy after completion of radiotherapy and/or surgical resection. Patients also undergo blood sample collection throughout the study. Additionally, patients may also undergo CT, PET/CT, and MRI with or without CT throughout the study at treating clinician's discretion.

Experimental: Cohort B (definitive radiotherapy, surgical resection)

Patients may receive SOC chemotherapy every 2 weeks for at least 3 cycles prior to radiotherapy. Patients with tumor size \< 8cm at diagnosis undergo definitive radiotherapy or surgical resection. Patients may also receive consolidation chemotherapy after completion of definitive radiotherapy or surgical resection. Patients also undergo blood sample collection throughout the study. Additionally, patients may also undergo CT, PET/CT, and MRI with or without CT throughout the study at treating clinician's discretion.

Experimental: Cohort C (radiotherapy, surgical resection)

Patients may receive SOC chemotherapy every 2 weeks for at least 3 cycles prior to radiotherapy. Patients undergo radiotherapy before or after undergoing definitive surgical resection. Patients may also receive consolidation chemotherapy after completion of definitive radiotherapy and surgical resection. Patients also undergo blood sample collection throughout the study. Additionally, patients may also undergo CT, PET/CT, and MRI with or without CT throughout the study at treating clinician's discretion.

Related Therapeutic Areas

Adult Soft Tissue Sarcoma

Ewing Sarcoma

Osteosarcoma

Similar Clinical Trials

View All